BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:03 PM
 | 
Jun 02, 2009
 |  BC Extra  |  Clinical News

GSK's Armala meets Phase III RCC endpoint

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) reported that Armala pazopanib met the primary endpoint of median progression-free survival (PFS)...

Read the full 73 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >